A Phase 2 interventional study of XEN-D0501 and Placebo in Chronic Idiopathic Cough, sponsored by Xention Ltd. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-15.
Sponsored by Xention Ltd · Phase 2, Interventional, and Treatment
The purpose of this study is to determine the effectiveness of XEN-D0501 over placebo in reducing the daytime cough frequency in patients with chronic idiopathic cough.
The effectiveness of XEN-D0501 over placebo in reducing capsaicin cough responses, objective 24-hour cough frequency, hourly change in cough frequency, cough severity (via visual analogue scale [VAS]), urge to cough (via VAS), global rating of change scale and Leicester Cough Questionnaire (LCQ) will be evaluated.
346 studies on the registry are indexed under Cough; 71 are open to participants now.
This study's enrollment of 18 is below the median of 70 across 263 interventional studies indexed under Cough.
Browse Cough studies →Xention Ltd is the lead sponsor of 9 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
4mg BID Days 1-13, 4mg once daily (OD) Day 14
Drug: XEN-D0501
BID Days 1-13, once daily (OD) Day 14
Drug: Placebo
Change from baseline at the end of each treatment period in objective daytime cough frequency on XEN-D0501 compared to placebo
Time frame: 12 weeks
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xention Ltd